{
  "success": true,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective 1",
        "text": "to compare OS in subjects with squamous cell carcinoma of the esophagus.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Objective 2",
        "text": "To compare OS in subjects with PD-L1 Combined Positive Score (CPS)≥10.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Primary Objective 3",
        "text": "To compare OS in all subjects.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective 1",
        "text": "To evaluate the progression free survival (PFS) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective 2",
        "text": "To evaluate the Objective Response Rate (ORR) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective 3",
        "text": "To evaluate the PFS and ORR per RECIST 1.1 assessed by central vendor review in subjects with squamous cell carcinoma of the esophagus and subjects with PD-L1 CPS≥10, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective 4",
        "text": "Evaluate the safety and tolerability profile of pembrolizumab in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Objective 1",
        "text": "To evaluate PFS per irRECIST assessed by blinded central vendor review in all subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Objective 2",
        "text": "To evaluate efficacy by GEP expression.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 3",
        "text": "To explore the concordance of PD-L1 in archival compared to newly obtained tumor tissue.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 4",
        "text": "To evaluate score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective 5",
        "text": "To characterize utilities using EuroQol EQ-5D among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_13",
        "name": "Exploratory Objective 6",
        "text": "To explore the relationship between genetic variation and response to the treatment administered. Variation across the human genome will be analyzed for association with clinical data collected in this study.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Overall Survival (OS)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint - PFS",
        "text": "Progression free survival (PFS) per RECIST 1.1 as assessed by the central imaging vendor",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint - ORR",
        "text": "Objective response rate (ORR) per RECIST 1.1 as assessed by the central imaging vendor",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Safety Endpoint",
        "text": "Safety and tolerability (toxicities as defined by CTCAE version 4.0, SAEs, and ECIs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Exploratory Endpoint - irRECIST",
        "text": "PFS per irRECIST assessed by blinded central vendor review",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Exploratory Endpoint - GEP",
        "text": "Efficacy by GEP expression",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Endpoint - PD-L1 Concordance",
        "text": "Concordance of PD-L1 in archival compared to newly obtained tumor tissue",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_8",
        "name": "Exploratory Endpoint - QoL",
        "text": "Score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Endpoint - EQ-5D",
        "text": "Utilities using EuroQol EQ-5D",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Endpoint - Genetic",
        "text": "Relationship between genetic variation and response to the treatment administered",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - OS (SCC)",
        "populationSummary": "Subjects with advanced/metastatic squamous cell carcinoma of the esophagus (ITT) Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues treatment for reasons other than death",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of non-study cancer treatment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "Subjects with advanced/metastatic squamous cell carcinoma of the esophagus (ITT)",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand - OS (PD-L1 CPS≥10)",
        "populationSummary": "Subjects with PD-L1 Combined Positive Score (CPS) ≥ 10 Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues treatment for reasons other than death",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "Subjects with PD-L1 Combined Positive Score (CPS) ≥ 10",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - PFS",
        "populationSummary": "All randomized subjects (ITT) Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death due to any cause prior to progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "New anti-cancer therapy",
            "text": "Initiation of new anti-cancer therapy prior to documented progression",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "All randomized subjects (ITT)",
        "variableOfInterest": "Progression-free survival (PFS) per RECIST 1.1 by central vendor",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_4",
        "name": "Safety Estimand",
        "populationSummary": "All randomized subjects who received at least one dose of study treatment Summary measure: Risk Difference / Proportion of subjects with events.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "All randomized subjects who received at least one dose of study treatment",
        "variableOfInterest": "Safety and tolerability (CTCAE v4.0 toxicities, SAEs, ECIs)",
        "summaryMeasure": "Risk Difference / Proportion of subjects with events"
      }
    ],
    "summary": {
      "primaryObjectives": 3,
      "secondaryObjectives": 4,
      "exploratoryObjectives": 6,
      "totalEndpoints": 10,
      "totalEstimands": 4
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective 1",
        "text": "to compare OS in subjects with squamous cell carcinoma of the esophagus.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Objective 2",
        "text": "To compare OS in subjects with PD-L1 Combined Positive Score (CPS)≥10.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Primary Objective 3",
        "text": "To compare OS in all subjects.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective 1",
        "text": "To evaluate the progression free survival (PFS) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective 2",
        "text": "To evaluate the Objective Response Rate (ORR) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective 3",
        "text": "To evaluate the PFS and ORR per RECIST 1.1 assessed by central vendor review in subjects with squamous cell carcinoma of the esophagus and subjects with PD-L1 CPS≥10, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective 4",
        "text": "Evaluate the safety and tolerability profile of pembrolizumab in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Objective 1",
        "text": "To evaluate PFS per irRECIST assessed by blinded central vendor review in all subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Objective 2",
        "text": "To evaluate efficacy by GEP expression.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 3",
        "text": "To explore the concordance of PD-L1 in archival compared to newly obtained tumor tissue.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 4",
        "text": "To evaluate score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective 5",
        "text": "To characterize utilities using EuroQol EQ-5D among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_13",
        "name": "Exploratory Objective 6",
        "text": "To explore the relationship between genetic variation and response to the treatment administered. Variation across the human genome will be analyzed for association with clinical data collected in this study.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Overall Survival (OS)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint - PFS",
        "text": "Progression free survival (PFS) per RECIST 1.1 as assessed by the central imaging vendor",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint - ORR",
        "text": "Objective response rate (ORR) per RECIST 1.1 as assessed by the central imaging vendor",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Safety Endpoint",
        "text": "Safety and tolerability (toxicities as defined by CTCAE version 4.0, SAEs, and ECIs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Exploratory Endpoint - irRECIST",
        "text": "PFS per irRECIST assessed by blinded central vendor review",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Exploratory Endpoint - GEP",
        "text": "Efficacy by GEP expression",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_7",
        "name": "Exploratory Endpoint - PD-L1 Concordance",
        "text": "Concordance of PD-L1 in archival compared to newly obtained tumor tissue",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_8",
        "name": "Exploratory Endpoint - QoL",
        "text": "Score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_9",
        "name": "Exploratory Endpoint - EQ-5D",
        "text": "Utilities using EuroQol EQ-5D",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Exploratory Endpoint - Genetic",
        "text": "Relationship between genetic variation and response to the treatment administered",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - OS (SCC)",
        "populationSummary": "Subjects with advanced/metastatic squamous cell carcinoma of the esophagus (ITT) Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues treatment for reasons other than death",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of non-study cancer treatment",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "Subjects with advanced/metastatic squamous cell carcinoma of the esophagus (ITT)",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_2",
        "name": "Primary Efficacy Estimand - OS (PD-L1 CPS≥10)",
        "populationSummary": "Subjects with PD-L1 Combined Positive Score (CPS) ≥ 10 Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues treatment for reasons other than death",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "Subjects with PD-L1 Combined Positive Score (CPS) ≥ 10",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - PFS",
        "populationSummary": "All randomized subjects (ITT) Summary measure: Hazard Ratio.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death due to any cause prior to progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "New anti-cancer therapy",
            "text": "Initiation of new anti-cancer therapy prior to documented progression",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "All randomized subjects (ITT)",
        "variableOfInterest": "Progression-free survival (PFS) per RECIST 1.1 by central vendor",
        "summaryMeasure": "Hazard Ratio"
      },
      {
        "id": "est_4",
        "name": "Safety Estimand",
        "populationSummary": "All randomized subjects who received at least one dose of study treatment Summary measure: Risk Difference / Proportion of subjects with events.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
        "analysisPopulation": "All randomized subjects who received at least one dose of study treatment",
        "variableOfInterest": "Safety and tolerability (CTCAE v4.0 toxicities, SAEs, ECIs)",
        "summaryMeasure": "Risk Difference / Proportion of subjects with events"
      }
    ]
  }
}